|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From Charité, Robert-Rössle-Klinik,
Humboldt University of Berlin; Max Delbrück Center for Molecular
Medicine, Berlin; Institute of Pathology, Klinikum Benjamin Franklin,
Free University of Berlin; Section of Experimental Surgery and
Immunology, Clinic for Surgery, University of Erlangen-Nürnberg,
Germany.
Notch signaling controls cell fate decisions of hematopoietic
progenitors by inhibiting certain steps of differentiation and inducing
either self-renewal or differentiation toward lymphoid or myeloid
lineages. In addition, truncated Notch1 alleles could be associated
with 10% of all cases of human T lymphoblastic leukemia and, when
introduced into mouse bone marrow stem cells, cause T-cell neoplasms.
However, functional links between the abundant expression of intact
Notch1 and oncogenesis are still lacking. Here we show that Notch1 is
highly expressed in B- and T-cell-derived tumor cells of Hodgkin and
anaplastic large cell lymphoma. We demonstrate a novel mechanism for
the oncogenic capacity of Notch1 by showing that the interaction
between intact Notch1 on tumor cells and its ligand Jagged1
dramatically induces proliferation and inhibition of apoptosis in
vitro. We further provide evidence that in Hodgkin and anaplastic large
cell lymphoma, Jagged1 is expressed in malignant and in bystander cells
colocalizing with Notch1-positive tumor cells. Notch1 signaling may
therefore be activated in tumor cells by Jagged1 through homotypic or
heterotypic cell-cell interactions, and it seems likely that these
interactions contribute to lymphomagenesis in vivo. Thus, our data
suggest that activated Notch1 signaling plays an important role in the pathobiology of Hodgkin and anaplastic large cell lymphoma and that it
might be a potential new target for treatment.
(Blood. 2002;99:3398-3403) Hodgkin and Reed-Sternberg (HRS) cells represent
clonal progeny of germinal center B cells in most cases of classical
Hodgkin disease (cHD).1,2 It has further been demonstrated
that HRS cells contain nonfunctional immunoglobulin (Ig) genes,
suggesting that they are derived from germinal center cells that should
have been negatively selected but were rescued from apoptosis by
cellular transforming events.3,4
Our previous work has provided evidence that constitutive NF- Notch1 belongs to a family of transmembrane receptors that control cell
proliferation and differentiation in response to extracellular ligands
expressed on neighboring cells.14-18 Notch1 has been
isolated as a translocation in human acute T-cell lymphoblastic
leukemia-lymphoma,19 and its constitutively active form
produces T-cell neoplasms in mice.20 These truncated
Notch1 proteins have been implicated in the transformation of rat
kidney cells through cooperation with adenoviral oncogene
E1A.21 In addition, transgenic mice that express the
Notch3 intracellular domain under lck promoter control
develop aggressive T-cell lymphomas, with tumor cells showing
constitutive NF- Here we show that Notch1 is strongly expressed in B-cell-derived HRS
cells and in tumor cells of T-cell-derived anaplastic large cell
lymphoma (ALCL). Our data indicate that the activation of Notch1
signaling in tumor cells by its ligand Jagged1 regulates tumor cell
growth and survival. We suggest that pharmacologic manipulation of the
Notch1 system might have therapeutic potential in these lymphomas.
Cell culture
HtTA-jag10 cells expressing human Jagged1 under tetracycline control,
as described previously,13 (HeLa-derived cell line) were
maintained in Dulbecco modified Eagle medium (DMEM)
supplemented with 10% fetal calf serum, hygromycin (225 U/mL;
Calbiochem, Bad Soden, Germany), G418 (125 µg/mL; Gibco), and
tetracycline (2 µg/mL; Sigma, Deisenhofen, Germany). For
cocultivation assays HtTA-jag10 cells were plated in 10-cm dishes.
Jagged1 expression was induced by washing HtTA-jag10 cells 3 times with
DMEM without tetracycline 24 hours and 48 hours after plating. After 72 hours, cells were cocultured with lymphoma cell lines
(2.0 × 106 cells/dish) for 48 hours. Lymphoma cells that
were aggregated onto the HtTA-jag10 monolayer were harvested by firm
tapping before RNA extraction.
Immunohistochemistry
In situ hybridization The cRNA probe was prepared by subcloning a human Jagged1 gene cDNA fragment (834 base pair [bp]) in the run-off transcription vector pGEM-T (Promega Biotec, Heidelberg, Germany). After linearization, run-off antisense transcripts with the incorporation of 35S-labeled UTP were generated using T7 RNA polymerases (Promega-Biotech, Madison, WI). In situ hybridization for the detection of Jagged1 transcripts was performed using microwave irradiation before the hybridization. Slides were hybridized with 4 × 105 cpm of labeled probes overnight at 50°C.Immunoblotting Cell extracts were prepared and quantitated as described.7 Proteins (20 µg) were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and were transferred to nitrocellulose membranes. Protein load was normalized by Ponceau red staining. Membranes were incubated with rat monoclonal anti-Notch1 antibodies (bTAN 20) and anti-Notch2 antibodies (bhN6D), followed by goat antirat horseradish peroxidase-conjugated antibodies (Dianova, Hamburg, Germany), and were detected by enhanced chemiluminescence (Amersham Pharmacia, Freiburg, Germany).Northern blot analysis Total RNA preparations were performed using the guanidinium isothiocyanate-phenol chloroform method as described previously.8 For Northern blot analysis, 10 µg total RNA was subjected to gel electrophoresis on a 1.1% formaldehyde-1.2% agarose gel and was transferred to a nylon membrane (Appligene, Heidelberg, Germany). After UV cross-linking, the membrane was prehybridized (ExpressHyb hybridization solution; Clontech, Heidelberg, Germany) at 68°C for 1 hour. Blots were hybridized with a 32P-random prime-labeled DNA probe overnight at 68°C. Probes were rat Hes-1 (723 bp of coding region) and human GAPDH (249 bp of coding region) cDNAs. Membranes were washed for 40 minutes at room temperature in 2 × SSC and 0.1% SDS and then for 40 minutes at 50°C in 0.5% SSC and 0.1% SDS.Proliferation assay HtTA-jag10 cells were plated in microtiter wells (2 × 103 cells/100 µL DMEM). Plates were washed with DMEM without tetracycline for the induction of Jagged1 after 24 and 48 hours. After 72 hours, HtTA-jag10 cells were irradiated with 100 Gy and were cocultured with lymphoma cells (2-4 × 104 cells/well). Triplicate samples were cultured for 24 hours at 37 °C in the presence or absence of tetracycline. 3[H] thymidine (1µCi [3.7 MBq]/100 µL DMEM) was added to each well for 20 hours before a determination was made of radioisotope incorporation into DNA. Soluble human Jagged1 was kindly provided by Seiji Sakano (Asahi Kasei, Shizuoka, Japan). This ligand is a fusion protein in which the extracellular domain of Jagged1 was fused in frame to the Fc part of human IgG1 (hJagged1-IgG). To cluster soluble ligand molecules, we used mouse L cells, stably expressing Fc gamma RII/CDw32.22 Then 2 × 104 L cells were seated in 96-well microtiter plates and irradiated with 75 Gy, after which 10µg/mL human IgG (control treated) or soluble hJagged1-IgG was coated onto the L-cell monolayer for 1 hour at 37°C. Plates were washed with PBS, and lymphoma cells were cocultured with L cells. Twenty-four hours later, 3[H] thymidine (1µCi [3.7 MBq]/100 µL DMEM) was added to each well for another 20 hours before a determination was made of radioisotope incorporation into DNA.Apoptosis assay After the induction of apoptosis by 10 µM sodium arsenite (Sigma), cocultured cells were harvested and washed with PBS. CD30+ HRS cells were detected with human monoclonal anti-CD30 antibodies (DAKO, Glostrup, Denmark) and stained with F(ab)2 phycoerythrin (PE)-conjugated antispecies IgG (Dianova). Free-binding groups of the secondary antibody were blocked by incubating cells with 10% mouse serum. Apoptotic cells were stained for 15 minutes with fluorescein isothiocyanate-labeled annexin V (Bender MedSystems, Vienna, Austria). Data were collected and analyzed with Becton Dickinson FACScan and CellQuest software (Becton Dickinson, Heidelberg, Germany).
Notch1 is highly expressed in tumor cells of Hodgkin and anaplastic large cell lymphoma We analyzed Notch1 expression in 25 cases of B-cell-derived cHD using a monoclonal antibody specific for the intracellular domain of Notch1 (Table 1). Applying immunohistochemistry we observed intensive Notch1 staining in HRS cells in all 25 cases of cHD, including nodular sclerosis and mixed cellularity subtypes (Figure 1A-B), though we found low to undetectable levels of immunoreactivity for Notch1 in reactive lymphoid tissues that served as a negative control (Figure 1D). Because infection with Epstein-Barr virus (EBV) has been linked to the pathogenesis of HD23 and because EBV nuclear antigen 2 (EBNA-2) and activated Notch1 are regarded as functional homologs that deregulate B-cell-specific gene expression,24 we were interested to know whether the expression of Notch1 correlates with EBV infection. However, we could not observe any correlation between these parameters using our immunohistochemical data (Table 1). Interestingly, using immunohistochemistry and in situ hybridization, we found abundant protein and mRNA expression of the Notch1 ligand, Jagged1, in HRS cells (Figure 1E), in endothelial and smooth muscle cells (Figure 1F), and in epithelioid cells neighboring HRS cells. These data suggest that Jagged1-induced Notch1 signaling might contribute to the pathobiology of cHD.
In contrast, in 8 cases of B-cell-derived sporadic Burkitt lymphoma (BL) associated with c-Myc deregulation, which is critical for malignant transformation and is known to collaborate with Notch1 for oncogenesis of murine T-cell tumors,25 tumor cells showed low to undetectable levels of Notch1 expression (Table 1). In addition, in most cases of other B-cell-derived non-Hodgkin lymphoma entities, we detected only weak immunoreactivity for Notch1 in tumor cells when compared to Notch1 highly expressed in HRS cells (Table 1). Interestingly, the tumor cells of all cases of T-cell-derived ALCL were also intensely labeled by Notch1 antibodies (Figure 1C). CD30+ ALCL resembles HD because of the CD30+ tumor cell immunophenotype and the presence of occasional RS cells.23 High expression levels of Notch1 in ALCL were independent of the presence or absence of the unique translocation t(2;5) (Table 1) that involves the fusion of the nucleophosmin gene NPM to an anaplastic lymphoma kinase (ALK) regarded as an important transforming event of most ALCLs.23 Using immunohistochemistry, we further showed that ALCL tumor cells were also positive for the Notch1 ligand Jagged1 in all cases tested (Figure 1G). Notch1 signaling is activated by Jagged1 in cultured HRS and ALCL cells To verify high Notch1 expression in lymphoma-derived cell lines, we performed Western blot analysis using Notch1 antibodies directed against the intracellular domain of the receptor. Apart from the inactive full-length protein (300 kd), we detected as the predominant species a 110-kd fragment (Figure 2A, upper panel). This fragment represents the transmembrane and intracellular domains (NTM) and results, along with the extracellular fragment (NEC), from proteolytic cleavage of full-length Notch1. NTM and NEC are linked together and appear as the active ligand-accessible form of the receptor on the cell surface.26 In cultured HRS cells (Figure 2A; lanes 1-5), we observed high expression of NTM when compared with mature CD19+ B cells (Figure 2A; lane 12). In addition, both ALCL cell lines (Figure 2A; lanes 6,7) displayed higher amounts of NTM than did their normal counterparts (Figure 2A; lane 11). In contrast, neither the BL cell lines (Figure 2A; lanes 8,9) nor the myeloma cell line (Figure 2A; lane 10) expressed significant levels of Notch1. Similarly, we observed higher Notch2 protein expression in HRS and ALCL cells than in BL cells and peripheral blood lymphocytes (Figure 2A, lower panel). These results are in accordance with a previous report showing by microarray experiments that in HD cell lines (L428, KM-H2, and HD-LM2), the expression of Notch2 mRNA is increased compared with lymphoblastoid EBV-infected B-cell lines.27 Our data here indicate that the cell lines derived from HD, ALCL, and BL used in this study resemble tumor cells in vivo with respect to Notch1 expression. They might represent a valuable model by which to assess Notch1-associated pathobiologic mechanisms in vitro. However, in contrast to primary HRS and ALCL cells, cultured tumor cells showed low to undetectable levels of the Notch1 ligand Jagged1 in Western blot analysis (data not shown).
To test whether Jagged1-induced Notch1 signaling directly activates downstream target genes,13 we cultured HRS and ALCL cells in the presence of Jagged1 to study mRNA expression of the mammalian basic helix-loop-helix transcription factor, hairy enhancer of split (Hes-1; Figure 2B). To that end we performed cocultivation assays using feeder cells expressing Jagged1 under tetracycline control (HtTA-jag10 cells)13 and Notch1-expressing lymphoma cells. Using Northern blot analysis, we demonstrated that in cultured HRS and ALCL cells, Hes-1-specific transcripts were up-regulated (Figure 2B, lanes 1-6; Figure 2C, lanes 7-10) after the induction of Jagged1 by tetracycline. This phenomenon was not observed in myeloma cells that did not express Notch1 (Figure 2B; lanes 11,12). Taken together, these data strongly suggest that intact Notch1 signaling of cultured HRS and ALCL cells can be induced by the ligand expressed on neighboring cells. Activated Notch1 signaling accelerates growth and inhibits arsenite-induced apoptosis of lymphoma cells As we observed the co-expression of Jagged1 and Notch1 in tumor cells and the colocalization of Jagged1-expressing bystander cells and Notch1-positive tumor cells on tumor biopsy specimens, we investigated the biologic significance of the functional interaction between Notch1 and Jagged1. One important role of the aberrant high expression of Notch1 in tumor cells of HD and ALCL may be to mimic a continuous growth-promoting signal. To study whether the activation of highly expressed Notch1 by Jagged1 would affect cell growth, we performed proliferation assays and measured 3[H] thymidine uptake using the cocultivation assay described above. Surprisingly, stimulation by Jagged1 dramatically increased the proliferation rates of HRS and ALCL cells up to 2- or even 3-fold in 20 hours compared with unstimulated controls (Figure 3A). Because the cell-cycle progression of these cell lines normally lasts between 40 and 48 hours, our data indicate an exponential increase in proliferation rates. These data were confirmed through comparison of the actual cell numbers of Jagged1-induced and -uninduced lymphoma cells (data not shown). In contrast, we could not induce a significant proliferative response in BL or myeloma cell lines. To further address whether the promotion of growth did not occur through the engagement of Notch on target cells but through Jagged1 on feeder cells which also
activated Notch signaling on the feeder cells and thereby changed the
expression of other proteinswe used purified, clustered, soluble
Jagged1 (Figure 3B). Stimulation of HD and ALCL cells by
soluble Jagged1 increased their proliferation rates up to 3-fold
compared to control treatment. These data confirm our results with
Jagged1-expressing feeder cells and demonstrate that soluble Jagged1 is
a potent growth factor for Notch-expressing lymphoma cells. We conclude
that the interaction between Jagged1 and intact Notch1 strongly
accelerates the proliferation of HRS and ALCL cells and may, therefore,
contribute to a transformation process in vivo.
Moreover, there is substantial evidence that, apart from the
involvement of Notch1 in proliferation events, programmed cell death
can be affected by Notch1 signaling.14,15 Given that, we
used the above-described cocultivation assay and tested whether activated Notch1 inhibits the susceptibility of HRS cells to
arsenite-induced apoptosis. We used this compound because it can
promote apoptosis through the inhibition of NF-
In this study we analyzed Notch1 expression in human malignant B- and T-cell lymphoma entities. We show here that Notch1 protein is highly expressed in tumor cells of cHD and ALCL and that the Notch1 ligand, Jagged1, is expressed in primary HRS and ALCL cells and in bystander cells neighboring tumor cells. Although Notch and its ligands are often expressed on the same cell, it has been shown that Notch is activated primarily through binding to its ligand on adjacent cells.29 It seems conceivable, therefore, that Notch1 signaling can be activated by Jagged1 in primary HRS and ALCL cells through homotypic or heterotypic cell-cell interactions. Notch interactions cause a dramatic increase in growth rates of cultured HRS and ALCL cells and might also influence tumor biology. HRS cells are known to produce cell surface receptors and cytokines to
create their own reactive cell microenvironment, which contributes to
stimulation of their growth and survival. We recently described that
HRS cells induce fibroblasts by tumor necrosis factor- In addition, our data show that activated Notch1 signaling induces expression of the downstream target gene, Hes-1, in cultured HRS and ALCL cells. Given the colocalization of Jagged1-expressing cells and Notch1-positive tumor cells in malignant lymphoid tissue, it seems likely that this interaction also leads to activated Notch1 signaling in vivo. Our data suggest that Jagged1-induced Notch1 signaling might contribute to the pathobiology of cHD and ALCL. Our study reveals a novel mechanism for potential oncogenic activity of Notch1 not only in T-cell but also in B-cell neoplasms. We have shown that Notch1 signaling, activated by its ligand Jagged1, dramatically accelerates the growth and inhibits the apoptosis of cHD and ALCL tumor cells. It has been shown that the increased expression of Notch1 is associated with the transformed phenotype of epithelial cells in cervical, lung squamous, and colon adenocarcinomas.33 Furthermore, a series of recent studies revealed that Notch influences apoptosis and proliferation.11,14,34-37 Our data indicate that direct ligand receptor interactions can account for the oncogenic capacity of Notch1. It is, however, conceivable that Notch1-induced transformation of hematopoietic lineages requires the collaborative action of additional cellular oncogenes.38 Recently, Jagged1 has been identified as a novel growth factor of human stem cells.18 This study provides evidence that Jagged1 can maintain and expand primitive hematopoietic cells capable of multilineage reconstitution in vivo.18 Given the great potential of Jagged1 to enhance the proliferation and survival of HRS cells in vitro, it is feasible that Jagged1-expressing monolayers can facilitate the difficult generation of new Hodgkin cell lines from primary biopsy samples. Studies to prove this hypothesis are under way. In normal hematopoiesis, activation of the Notch pathway can result in
a block of differentiation.14-16 HRS cells originate from
single clones of germinal center B cells because they have functional
immunoglobulin gene rearrangements and carry high loads of somatic
immunoglobulin mutations. However, despite the presence of clonal
immunoglobulin rearrangements, immunoglobulin transcription is
impaired, correlating with the down-regulated synthesis of the B-cell
transcription factors BOB.1/OBF.1 and Oct2.39 Because Notch1 signaling down-regulates Igµ expression,24,40 it
is possible that Notch1 interrupts the differentiation process of HRS
cells, and this may act in concert with constitutively activated NF- Finally, this study suggests that the down-regulation of Notch1 signaling may be used to control proliferation and to enhance apoptosis of tumor cells of cHD and ALCL. Modulation of the Notch pathway may provide a valuable tool to manipulate the transformed state of malignant lymphatic cells, thereby potentially offering a novel therapeutic approach.
We thank Katharina Kley for excellent technical assistance; Dr Kurt Bommert for comments on the manuscript; Dr Hans-Dieter Foss for performing Jagged1-encoded in situ hybridization; and Dr Celine Gelinas from the University of Medicine and Dentistry of New Jersey for the gift of HtTA-jag10 cells. Soluble human Jagged1 was kindly provided by Seiji Sakano (Asahi Kasei, Shizuoka, Japan).
Submitted August 3, 2001; accepted December 27, 2001.
Supported by grant JU 426/1-1 from the Deutsche Forschungsgemeinschaft.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Franziska Jundt, Charité, Robert-Rössle-Klinik, Humboldt University of Berlin, D-13125 Berlin, Germany; e-mail: fjundt{at}mdc-berlin.de.
1.
Marafioti T, Hummel M, Anagnostopoulos I, et al.
Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell.
J Clin Oncol.
1999;17:3804-3809
2.
Bräuninger A, Hansmann ML, Strickler JG, et al.
Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma.
N Engl J Med.
1999;340:1239-1247 3. Küppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol. 1998;16:471-493[CrossRef][Medline] [Order article via Infotrieve].
4.
Marafioti T, Hummel M, Foss H-D, et al.
Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.
Blood.
2000;95:1443-1450
5.
Bargou RC, Mapara MY, Zugck C, et al.
Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice.
J Exp Med.
1993;177:1257-1268
6.
Bargou RC, Leng C, Krappmann D, et al.
High-level nuclear NF-
7.
Bargou RC, Emmerich F, Krappmann D, et al.
Constitutive nuclear factor-
8.
Jundt F, Anagnostopoulos I, Bommert K, et al.
Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils.
Blood.
1999;94:2065-2071
9.
Emmerich F, Meiser M, Hummel M, et al.
Overexpression of I
10.
Jungnickel B, Staratschek-Jox A, Bräuninger A, et al.
Clonal deleterious mutations in the I
11.
Bellavia D, Campese AF, Alesse E, et al.
Constitutive activation of NF-
12.
Guan E, Wang J, Laborda J, Norcross M, Baeuerle PA, Hoffman T.
T cell leukemia-associated human Notch/translocation-associated Notch homologue has I
13.
Bash J, Zong W-X, Banga S, et al.
Rel/NF-
14.
Artavanis-Tsakonas S, Rand MD, Lake RJ.
Notch signaling: cell fate control and signal integration in development.
Science.
1999;284:770-776
15.
Milner LA, Bigas A.
Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation.
Blood.
1999;93:2431-2448 16. Brenner M. To be or notch to be. Nat Med. 2000;6:1210-1211[CrossRef][Medline] [Order article via Infotrieve]. 17. Varnum-Finney B, Xu L, Brashem-Stein C, et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med. 2000;6:1278-1281[CrossRef][Medline] [Order article via Infotrieve].
18.
Karanu FN, Murdoch B, Gallacher L, et al.
The Notch ligand Jagged-1 represents a novel growth factor of human hematopoietic stem cells.
J Exp Med.
2000;192:1365-1372 19. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649-661[CrossRef][Medline] [Order article via Infotrieve].
20.
Pear WS, Aster JC, Scott ML, et al.
Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.
J Exp Med.
1996;183:2283-2291 21. Capobianco AJ, Zagouras P, Blaumueller CM, Artavanis-Tsakonas S, Bishop JM. Neoplastic transformation by truncated alleles of human Notch1/TAN1 and Notch2. Mol Cell Biol. 1997;17:6265-6273[Abstract].
22.
Banchereau J, de Paoli P, Vallé A, Garcia E, Rousset F.
Long term human B cell lines dependent on interleukin 4 and antibody to CD40.
Science.
1991;251:70-72 23. Gaidano G, Dalla-Favera R. Pathobiology of non-Hodgkin lymphomas. In: Hoffman R, ed. Hematology: Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone; 2000:1213-1229.
24.
Strobl LJ, Höfelmayr H, Marschall G, Brielmeier M, Bornkamm GW, Zimber-Strobl U.
Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2.
J Virol.
2000;74:1727-1735
25.
Girad L, Hanna Z, Beaulieu N, et al.
Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis.
Genes Dev.
1996;10:1930-1944 26. Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell. 1997;90:281-291[CrossRef][Medline] [Order article via Infotrieve].
27.
Kapp U, Yeh W-C, Patterson B, et al.
Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells.
J Exp Med.
1999;189:1939-1945
28.
Kapahi P, Takahashi T, Natoli G, et al.
Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of I 29. Heitzler P, Simpson P. The choice of cell fate in the epidermis of Drosophila. Cell. 1991;64:1083-1092[CrossRef][Medline] [Order article via Infotrieve]. 30. Pinto A, Aldinucci D, Gloghini A, et al. The role of eosinophils in the pathobiology of Hodgkin's disease. Ann Oncol. 1997;8:89-97.
31.
Hinz M, Löser P, Mathas S, et al.
Constitutive NF- 32. Craxton A, Otipoby KL, Jiang A, Clark EA. Signal transduction pathways that regulate the fate of B lymphocytes. Adv Immunol. 1999;73:79-152[Medline] [Order article via Infotrieve].
33.
Zagouras P, Stifani S, Blaumüller CM, Carcangiu ML, Artavanis-Tsakonas S.
Alterations in Notch signaling in neoplastic lesions of the human cervix.
Proc Natl Acad Sci U S A.
1995;92:6414-6418
34.
Morimura T, Goitsuka R, Zhang Y, et al.
Cell cycle arrest and apoptosis induced by Notch1 in B cells.
J Biol Chem.
2000;275:36523-36531 35. Miele L, Osborne B. Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol. 1999;181:393-409[CrossRef][Medline] [Order article via Infotrieve]. 36. Shelly LL, Fuchs C, Miele L. Notch-1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced hybrid polar compounds.
37.
Jehn BM, Bielke W, Pear WS, Osborne BA.
Cutting edge: protective effects of notch-1 on TCR-induced apoptosis.
J Immunol.
1999;162:635-638
38.
Feldman BJ, Hampton T, Cleary ML, et al.
A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice.
Blood.
2000;96:1906-1913
39.
Stein H, Marafioti T, Foss H-D, et al.
Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.
Blood.
2001;97:496-501
40.
Morimura T, Miyatani S, Kitamura D, Goitsuka R.
Notch signaling suppresses IgH gene expression in chicken B cells: implication in spatially restricted expression of Serrate2/Notch1 in the bursa of Fabricius.
J Immunol.
2001;166:3277-3283
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  C. C. Pinnix, J. T. Lee, Z.-J. Liu, R. McDaid, K. Balint, L. J. Beverly, P. A. Brafford, M. Xiao, B. Himes, S. E. Zabierowski, et al. Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes Cancer Res., July 1, 2009; 69(13): 5312 - 5320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kohlhof, F. Hampel, R. Hoffmann, H. Burtscher, U. H. Weidle, M. Holzel, D. Eick, U. Zimber-Strobl, and L. J. Strobl Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells Blood, May 28, 2009; 113(22): 5506 - 5515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xiao, L. Ning, and H. Chen Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors Mol. Cancer Ther., February 1, 2009; 8(2): 350 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rosati, R. Sabatini, G. Rampino, A. Tabilio, M. Di Ianni, K. Fettucciari, A. Bartoli, S. Coaccioli, I. Screpanti, and P. Marconi Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells Blood, January 22, 2009; 113(4): 856 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nefedova, D. M. Sullivan, S. C. Bolick, W. S. Dalton, and D. I. Gabrilovich Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy Blood, February 15, 2008; 111(4): 2220 - 2229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-M. Zhu, W.-L. Zhao, J.-F. Fu, J.-Y. Shi, Q. Pan, J. Hu, X.-D. Gao, B. Chen, J.-M. Li, S.-M. Xiong, et al. NOTCH1 Mutations in T-Cell Acute Lymphoblastic Leukemia: Prognostic Significance and Implication in Multifactorial Leukemogenesis. Clin. Cancer Res., May 15, 2006; 12(10): 3043 - 3049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, Y. Zhang, Y. Li, S. Banerjee, J. Liao, and F. H. Sarkar Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther., March 1, 2006; 5(3): 483 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Zweidler-McKay, Y. He, L. Xu, C. G. Rodriguez, F. G. Karnell, A. C. Carpenter, J. C. Aster, D. Allman, and W. S. Pear Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies Blood, December 1, 2005; 106(12): 3898 - 3906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stuhmer, M. Chatterjee, M. Hildebrandt, P. Herrmann, H. Gollasch, C. Gerecke, S. Theurich, L. Cigliano, R. A. Manz, P. T. Daniel, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma Blood, November 15, 2005; 106(10): 3609 - 3617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Re, R. Kuppers, and V. Diehl Molecular Pathogenesis of Hodgkin's Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6379 - 6386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Cuevas, A. L. Slocum, P. Jun, J. F. Costello, A. W. Bollen, G. J. Riggins, M. W. McDermott, and A. Lal Meningioma Transcript Profiles Reveal Deregulated Notch Signaling Pathway Cancer Res., June 15, 2005; 65(12): 5070 - 5075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Atayar, S. Poppema, T. Blokzijl, G. Harms, M. Boot, and A. van den Berg Expression of the T-Cell Transcription Factors, GATA-3 and T-bet, in the Neoplastic Cells of Hodgkin Lymphomas Am. J. Pathol., January 1, 2005; 166(1): 127 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Poppema Immunobiology and Pathophysiology of Hodgkin Lymphomas Hematology, January 1, 2005; 2005(1): 231 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Houde, Y. Li, L. Song, K. Barton, Q. Zhang, J. Godwin, S. Nand, A. Toor, S. Alkan, N. V. Smadja, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines Blood, December 1, 2004; 104(12): 3697 - 3704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Hallahan, J. I. Pritchard, S. Hansen, M. Benson, J. Stoeck, B. A. Hatton, T. L. Russell, R. G. Ellenbogen, I. D. Bernstein, P. A. Beachy, et al. The SmoA1 Mouse Model Reveals That Notch Signaling Is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas Cancer Res., November 1, 2004; 64(21): 7794 - 7800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Noseda, L. Chang, G. McLean, J. E. Grim, B. E. Clurman, L. L. Smith, and A. Karsan Notch Activation Induces Endothelial Cell Cycle Arrest and Participates in Contact Inhibition: Role of p21Cip1 Repression Mol. Cell. Biol., October 15, 2004; 24(20): 8813 - 8822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. MacKenzie, P. Duriez, F. Wong, M. Noseda, and A. Karsan Notch4 Inhibits Endothelial Apoptosis via RBP-J{kappa}-dependent and -independent Pathways J. Biol. Chem., March 19, 2004; 279(12): 11657 - 11663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lathion, J. Schaper, P. Beard, and K. Raj Notch1 Can Contribute to Viral-Induced Transformation of Primary Human Keratinocytes Cancer Res., December 15, 2003; 63(24): 8687 - 8694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Lundell, H.-K. Lee, E. Perez, and L. Chadwell The regulation of apoptosis by Numb/Notch signaling in the serotonin lineage of Drosophila Development, September 1, 2003; 130(17): 4109 - 4121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Y. Huang, A. M. Gallegos, S. M. Richards, S. M. Lehar, and M. J. Bevan Surface Expression of Notch1 on Thymocytes: Correlation with the Double-Negative to Double-Positive Transition J. Immunol., September 1, 2003; 171(5): 2296 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Swanson-Mungerson, M. Ikeda, L. Lev, R. Longnecker, and T. Portis Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein-Barr virus (EBV)-associated diseases J. Antimicrob. Chemother., August 1, 2003; 52(2): 152 - 154. [Full Text] [PDF]
|
|
|
|
|
|
A. P. Weng, Y. Nam, M. S. Wolfe, W. S. Pear, J. D. Griffin, S. C. Blacklow, and J. C. Aster Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling Mol. Cell. Biol., January 15, 2003; 23(2): 655 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Portis and R. Longnecker Epstein-Barr Virus LMP2A Interferes with Global Transcription Factor Regulation When Expressed during B-Lymphocyte Development J. Virol., December 6, 2002; 77(1): 105 - 114. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
B
activity is a survival factor for HRS cells.
. HRS cells depleted
of constitutive nuclear NF-
80°C until use. CD19+ B
cells and CD2+ T cells were enriched using the Dynabead
system (Dynal, Hamburg, Germany). In brief, mononuclear cell suspension
was incubated at 4°C for 30 minutes with Dynabeads coated with a
monoclonal antibody specific for either the human B-cell-restricted
membrane antigen CD19 or the human T-cell surface marker CD2.
CD19+ and CD2+ cells were selected by a
magnetic separation device and were resuspended in PBS.
